|New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)|
EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ...
European journal of cancer 45 (2), 228-247, 2009
|New guidelines to evaluate the response to treatment in solid tumors|
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, ...
Journal of the National Cancer Institute 92 (3), 205-216, 2000
|Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study|
HU Ahmed, AES Bosaily, LC Brown, R Gabe, R Kaplan, MK Parmar, ...
The Lancet 389 (10071), 815-822, 2017
|Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial|
TS Maughan, RA Adams, CG Smith, AM Meade, MT Seymour, RH Wilson, ...
The Lancet 377 (9783), 2103-2114, 2011
|Participation of patients 65 years of age or older in cancer clinical trials|
JH Lewis, ML Kilgore, DP Goldman, EL Trimble, R Kaplan, MJ Montello, ...
Journal of clinical oncology 21 (7), 1383-1389, 2003
|Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group|
GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ...
Journal of Clinical Oncology 17 (11), 3461-3467, 1999
|Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates|
BF Hankey, EJ Feuer, LX Clegg, RB Hayes, JM Legler, PC Prorok, ...
Journal of the National Cancer Institute 91 (12), 1017-1024, 1999
|Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial|
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
|Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies|
S Venderbosch, ID Nagtegaal, TS Maughan, CG Smith, JP Cheadle, ...
Clinical Cancer Research 20 (20), 5322-5330, 2014
|Brain and other central nervous system cancers: recent trends in incidence and mortality|
JM Legler, LAG Ries, MA Smith, JL Warren, EF Heineman, RS Kaplan, ...
Journal of the National Cancer Institute 91 (16), 1382-1390, 1999
|Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas|
HA Fine, WD Figg, K Jaeckle, PY Wen, AP Kyritsis, JS Loeffler, VA Levin, ...
Journal of Clinical Oncology 18 (4), 708-708, 2000
|How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials|
WB Sateren, EL Trimble, J Abrams, O Brawley, N Breen, L Ford, ...
Journal of clinical oncology 20 (8), 2109-2117, 2002
|A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant …|
EA Chiocca, KM Abbed, S Tatter, DN Louis, FH Hochberg, F Barker, ...
Molecular Therapy 10 (5), 958-966, 2004
|Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08|
PY Wen, WKA Yung, KR Lamborn, PL Dahia, Y Wang, B Peng, LE Abrey, ...
Clinical Cancer Research 12 (16), 4899-4907, 2006
|Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results|
FF Lang, JM Bruner, GN Fuller, K Aldape, MD Prados, S Chang, ...
Journal of Clinical Oncology 21 (13), 2508-2518, 2003
|Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999|
DG Bostwick, DJ Grignon, MEH Hammond, MB Amin, M Cohen, ...
Archives of pathology & laboratory medicine 124 (7), 995-1000, 2000
|The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis|
JE Olson, CA Janney, RD Rao, JR Cerhan, PJ Kurtin, D Schiff, RS Kaplan, ...
Cancer 95 (7), 1504-1510, 2002
|Clinical trial designs for cytostatic agents: are new approaches needed?|
EL Korn, SG Arbuck, JM Pluda, R Simon, RS Kaplan, MC Christian
Journal of Clinical Oncology 19 (1), 265-272, 2001
|Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …|
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
|Prognostic indicators of colon tumors. The gastrointestinal tumor study group experience|
SM Steinberg, JS Barkin, RS Kaplan, DM Stablein
Cancer 57 (9), 1866-1870, 1986